Prot #CO39722: A Phase III, Open-Label, Multicenter, Two-Arm, Randomized Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Patients with Previously Untreated Advanced BRAFV600 Wild-Type Melanoma